BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28485019)

  • 1. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.
    Tasani M; Ancliff P; Glover M
    Br J Dermatol; 2017 Dec; 177(6):e344-e346. PubMed ID: 28485019
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
    Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
    Wang H; Guo X; Duan Y; Zheng B; Gao Y
    Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
    Wang Z; Li K; Dong K; Xiao X; Zheng S
    Pediatr Blood Cancer; 2014 Aug; 61(8):1518-9. PubMed ID: 24482015
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
    Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
    Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
    [No Abstract]   [Full Text] [Related]  

  • 6. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
    Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
    Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
    [No Abstract]   [Full Text] [Related]  

  • 7. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
    Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
    Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus.
    Wlodek C; Burt H; Shaw L
    Clin Exp Dermatol; 2017 Oct; 42(7):825-827. PubMed ID: 28703334
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma.
    Liu YX; Zhang J; Nie XL; Chen YL; Wang ZY; Xu ZG
    Australas J Dermatol; 2021 May; 62(2):e329-e331. PubMed ID: 33216947
    [No Abstract]   [Full Text] [Related]  

  • 10. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.
    Zhang X; Yang K; Chen S; Ji Y
    J Dermatol; 2019 Oct; 46(10):898-901. PubMed ID: 31373046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus: Case Report and Literature Review.
    Wang C; Li Y; Xiang B; Li F; Chen S; Li L; Ji Y
    Pancreas; 2017; 46(5):e39-e41. PubMed ID: 28426496
    [No Abstract]   [Full Text] [Related]  

  • 12. Image Gallery: Kaposiform haemangioendothelioma.
    Moscarella E; Ametrano O; Diplomatico M; De Chiara C; Capasso M; Errico ME; Picciocchi R
    Br J Dermatol; 2017 Jun; 176(6):e124. PubMed ID: 28581217
    [No Abstract]   [Full Text] [Related]  

  • 13. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
    Cashell J; Smink GM; Helm K; Xavier F
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaposiform haemangioendothelioma in an adult: lack of response to topical sirolimus and response to radiotherapy.
    Der Sarkissian SA; Wong XL; Kossard S; Hong A; Sebaratnam DF
    Clin Exp Dermatol; 2022 Jan; 47(1):192-193. PubMed ID: 34480811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of kaposiform hemangioendothelioma and tufted angioma.
    Liu XH; Li JY; Qu XH; Yan WL; Zhang L; Yang C; Zheng JW
    Int J Cancer; 2016 Oct; 139(7):1658-66. PubMed ID: 27252149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
    Ji Y; Chen S; Yang K; Xia C; Peng S
    J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Corticosteroid and Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma: A Systematic Review and Meta-Analysis.
    Yao W; Li K; Wang Z; Pei J; Liu X; Zheng S; Dong K
    Eur J Pediatr Surg; 2019 Oct; 29(5):401-407. PubMed ID: 30372769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
    Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
    Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
    Wang Y; Kong L; Sun B; Cui J; Shen W
    J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
    Kai L; Wang Z; Yao W; Dong K; Xiao X
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.